Cargando…
Hydroxychloroquine and chloroquine in COVID-19: should they be used as standard therapy?
The pandemic of the new coronavirus, known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has urged the nations to an unprecedented world-wide reaction, including an accelerated exploration of therapeutic options. In the absence of a vaccine and specifically designed antivirals, th...
Autores principales: | Ibáñez, Sebastián, Martínez, Oriela, Valenzuela, Francisca, Silva, Francisco, Valenzuela, Omar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7267470/ https://www.ncbi.nlm.nih.gov/pubmed/32495226 http://dx.doi.org/10.1007/s10067-020-05202-4 |
Ejemplares similares
-
Hydroxychloroquine in the post-COVID-19 era: will this pandemic upset decades of clinical practice?
por: Pothen, Lucie, et al.
Publicado: (2021) -
Evaluating the Use of Hydroxychloroquine in Treating Patients With Rheumatoid Arthritis
por: Nazir, Armaan M, et al.
Publicado: (2021) -
Hydroxychloroquine-Induced Myopathy Responding to Intravenous Immunoglobulin (IVIG)
por: Almoallim, Hani, et al.
Publicado: (2023) -
Are patients with rheumatologic diseases on chronic immunosuppressive therapy at lower risk of developing severe symptoms when infected with COVID-19?
por: Vakil-Gilani, Kiana, et al.
Publicado: (2020) -
Are antiphospholipid antibodies just a common epiphenomenon or are they causative of immune-mediated coagulopathy in COVID-19?
por: Castillo-Martínez, Diana, et al.
Publicado: (2021)